NASDAQ:OTIC - Otonomy Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.60 -0.15 (-4.00 %)
(As of 07/18/2018 04:00 PM ET)
Previous Close$3.65
Today's Range$3.55 - $3.72
52-Week Range$2.80 - $21.15
Volume5,302 shs
Average Volume351,104 shs
Market Capitalization$110.08 million
P/E Ratio-1.23
Dividend YieldN/A
Otonomy logoOtonomy, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for otology in the United States. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; and OTO- 313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed a Phase 1 clinical safety trial for the treatment of tinnitus. In addition, it develops OTO-413, a sustained exposure formulation of brain-derived neurotrophic factor for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties; OTO-5XX, an otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.

Receive OTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for OTIC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio16.24
Quick Ratio16.24


Trailing P/E Ratio-1.23
Forward P/E Ratio-2.05
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.24 million
Price / Sales88.78
Cash FlowN/A
Price / CashN/A
Book Value$3.87 per share
Price / Book0.93


EPS (Most Recent Fiscal Year)($2.97)
Net Income$-90,130,000.00
Net Margins-6,316.88%
Return on Equity-58.60%
Return on Assets-53.72%


Outstanding Shares30,580,000
Market Cap$110.08

The Truth About Cryptocurrencies

Otonomy (NASDAQ:OTIC) Frequently Asked Questions

What is Otonomy's stock symbol?

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

How were Otonomy's earnings last quarter?

Otonomy Inc (NASDAQ:OTIC) released its quarterly earnings data on Thursday, March, 8th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.67) by $0.05. The biopharmaceutical company had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.46 million. Otonomy had a negative return on equity of 58.60% and a negative net margin of 6,316.88%. The business's revenue was down 1.1% on a year-over-year basis. View Otonomy's Earnings History.

What price target have analysts set for OTIC?

4 analysts have issued twelve-month price targets for Otonomy's stock. Their predictions range from $8.00 to $15.00. On average, they anticipate Otonomy's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 177.8% from the stock's current price. View Analyst Ratings for Otonomy.

What is the consensus analysts' recommendation for Otonomy?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Are investors shorting Otonomy?

Otonomy saw a decrease in short interest during the month of June. As of June 29th, there was short interest totalling 727,991 shares, a decrease of 44.9% from the June 15th total of 1,321,378 shares. Based on an average trading volume of 576,927 shares, the short-interest ratio is currently 1.3 days. Approximately 2.8% of the company's shares are sold short. View Otonomy's Current Options Chain.

Who are some of Otonomy's key competitors?

Who are Otonomy's key executives?

Otonomy's management team includes the folowing people:
  • Dr. Jay B. Lichter, Co-Founder & Chairman (Age 56)
  • Dr. David Allen Weber, Pres, CEO & Director (Age 58)
  • Mr. Paul E. Cayer, Chief Financial & Bus. Officer (Age 56)
  • Dr. Kathie M. Bishop, Chief Scientific Officer (Age 52)
  • Dr. Allen F. Ryan Ph.D., Co-Founder and Member of the Advisory Panel

Has Otonomy been receiving favorable news coverage?

News articles about OTIC stock have trended somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Otonomy earned a news impact score of 0.12 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 47.75 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Otonomy?

Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Otonomy's stock price today?

One share of OTIC stock can currently be purchased for approximately $3.60.

How big of a company is Otonomy?

Otonomy has a market capitalization of $110.08 million and generates $1.24 million in revenue each year. The biopharmaceutical company earns $-90,130,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis. Otonomy employs 53 workers across the globe.

How can I contact Otonomy?

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]

MarketBeat Community Rating for Otonomy (NASDAQ OTIC)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  194 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  336
MarketBeat's community ratings are surveys of what our community members think about Otonomy and other stocks. Vote "Outperform" if you believe OTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OTIC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by Staff

Featured Article: How Short Selling Works

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.